Poseida Therapeutics, Inc. (PSTX)
NASDAQ: PSTX · Real-Time Price · USD
9.45
+0.04 (0.43%)
At close: Dec 20, 2024, 4:00 PM
9.36
-0.09 (-0.95%)
After-hours: Dec 20, 2024, 6:29 PM EST
Poseida Therapeutics Employees
Poseida Therapeutics had 330 employees as of December 31, 2023. The number of employees increased by 16 or 5.10% compared to the previous year.
Employees
330
Change (1Y)
16
Growth (1Y)
5.10%
Revenue / Employee
$457,145
Profits / Employee
-$184,118
Market Cap
921.06M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Owens & Minor | 22,200 |
The Pennant Group | 5,791 |
HealthStream | 1,092 |
Pacira BioSciences | 712 |
Gyre Therapeutics | 593 |
Zymeworks | 278 |
Nuvation Bio | 51 |
PSTX News
- 12 days ago - Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting - PRNewsWire
- 24 days ago - POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX - Business Wire
- 25 days ago - Poseida shares triple on Tuesday, boosted by Roche collaboration - Invezz
- 25 days ago - Why This Gene-Therapy Company's Stock Is Rising 228% - Barrons
- 25 days ago - Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details - Benzinga
- 25 days ago - Roche to acquire US-based Poseida Therapeutics - Reuters
- 25 days ago - Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies - GlobeNewsWire
- 25 days ago - Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc. - PRNewsWire